Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs

Structural Basis for Molecular Recognition at Serotonin Receptors

(2013) C. Wang et al.   SCIENCE

Structural Features for Functional Selectivity at Serotonin Receptors

(2013) D. Wacker et al.   SCIENCE

Update on Typical and Atypical Antipsychotic Drugs

(2012) Herbert Y. Meltzer   Annual Review of Medicine

Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease

(2012) Diana L. Price et al.   BEHAVIOURAL PHARMACOLOGY

Psychiatric syndromes in Parkinsonʼs disease

(2012) Sergio E. Starkstein et al.   CURRENT OPINION IN PSYCHIATRY

Identification of Multiple 5-HT4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease

(2012) Michael A. Brodney et al.   JOURNAL OF MEDICINAL CHEMISTRY

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

(2012) Herbert Y. Meltzer et al.   SCHIZOPHRENIA RESEARCH

Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors

(2011) John A. Allen et al.   Annual Review of Pharmacology and Toxicology

Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs

(2011) Miguel Fribourg et al.   CELL

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Discovery of  -Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy

(2011) J. A. Allen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease

(2010) G. Maher-Edwards et al.   Current Alzheimer Research

Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure

(2010) Corby K. Martin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Expanded Biology of Serotonin

(2009) Miles Berger et al.   Annual Review of Medicine

β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice

(2009) Robert W. Walters et al.   JOURNAL OF CLINICAL INVESTIGATION

Attenuation of Phencyclidine-Induced Object Recognition Deficits by the Combination of Atypical Antipsychotic Drugs and Pimavanserin (ACP 103), a 5-Hydroxytryptamine2A Receptor Inverse Agonist

(2009) S. Snigdha et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment

(2009) X.-P. Huang et al.   MOLECULAR PHARMACOLOGY

Predicting new molecular targets for known drugs

(2009) Michael J. Keiser et al.   NATURE

Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

(2009) Herbert Y Meltzer et al.   NEUROPSYCHOPHARMACOLOGY

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

(2009) Atheir I. Abbas et al.   PSYCHOPHARMACOLOGY

A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior

(2008) Jean-Martin Beaulieu et al.   CELL

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

(2008) W. J. Thomsen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS